Barclays PLC Has $5.77 Million Stake in Neogen Co. (NASDAQ:NEOG)

Barclays PLC boosted its position in Neogen Co. (NASDAQ:NEOG - Free Report) by 29.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 475,365 shares of the company's stock after purchasing an additional 108,612 shares during the period. Barclays PLC owned 0.22% of Neogen worth $5,771,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of NEOG. Harbour Investments Inc. acquired a new position in shares of Neogen in the fourth quarter valued at approximately $27,000. Blue Trust Inc. increased its position in Neogen by 196.7% in the 4th quarter. Blue Trust Inc. now owns 3,368 shares of the company's stock valued at $41,000 after acquiring an additional 2,233 shares during the period. Covestor Ltd raised its stake in shares of Neogen by 41.4% during the fourth quarter. Covestor Ltd now owns 4,103 shares of the company's stock valued at $50,000 after acquiring an additional 1,202 shares during the last quarter. KBC Group NV lifted its holdings in shares of Neogen by 39.1% during the fourth quarter. KBC Group NV now owns 8,464 shares of the company's stock worth $103,000 after purchasing an additional 2,379 shares during the period. Finally, Brown Brothers Harriman & Co. grew its stake in shares of Neogen by 4,955.8% in the fourth quarter. Brown Brothers Harriman & Co. now owns 10,415 shares of the company's stock worth $126,000 after purchasing an additional 10,209 shares during the last quarter. 96.73% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, insider Amy M. Rocklin purchased 12,500 shares of the company's stock in a transaction that occurred on Wednesday, April 23rd. The shares were acquired at an average cost of $4.99 per share, with a total value of $62,375.00. Following the purchase, the insider now owns 36,287 shares in the company, valued at $181,072.13. This represents a 52.55 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director James P. Tobin acquired 10,000 shares of Neogen stock in a transaction on Tuesday, April 22nd. The stock was purchased at an average cost of $4.73 per share, with a total value of $47,300.00. Following the purchase, the director now directly owns 37,474 shares of the company's stock, valued at approximately $177,252.02. This trade represents a 36.40 % increase in their position. The disclosure for this purchase can be found here. Insiders have purchased a total of 67,500 shares of company stock valued at $331,525 over the last ninety days. 1.13% of the stock is owned by corporate insiders.

Neogen Trading Down 0.1 %

NEOG traded down $0.01 during trading on Thursday, reaching $5.05. 791,045 shares of the stock traded hands, compared to its average volume of 2,770,603. The stock's 50-day moving average is $7.70 and its 200 day moving average is $11.05. Neogen Co. has a 12 month low of $3.87 and a 12 month high of $18.58. The company has a quick ratio of 2.46, a current ratio of 3.77 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $1.09 billion, a PE ratio of -2.31 and a beta of 1.57.

Neogen (NASDAQ:NEOG - Get Free Report) last released its earnings results on Wednesday, April 9th. The company reported $0.10 EPS for the quarter, missing the consensus estimate of $0.12 by ($0.02). The business had revenue of $221.00 million for the quarter, compared to analyst estimates of $225.27 million. Neogen had a positive return on equity of 2.89% and a negative net margin of 52.12%. The company's revenue for the quarter was down 3.4% on a year-over-year basis. During the same period in the prior year, the business earned $0.12 EPS. Equities analysts anticipate that Neogen Co. will post 0.38 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on NEOG. Piper Sandler cut their target price on Neogen from $6.40 to $5.00 and set a "neutral" rating on the stock in a report on Tuesday, April 22nd. Guggenheim cut their price objective on Neogen from $15.00 to $13.00 and set a "buy" rating on the stock in a research note on Thursday, April 10th.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.